Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cjca.2024.12.010 | DOI Listing |
J Cardiovasc Dev Dis
January 2025
Cardiovascular Center, Cathay General Hospital, Taipei 106, Taiwan.
Background: A staging system based on cardiac damage for severe aortic stenosis (AS) has been validated for prognosis prediction following transcatheter aortic valve replacement (TAVR). Our study aims to investigate whether TAVR can lead to changes in cardiac damage shortly after the procedure and how these changes impact prognosis.
Method: Patients in this retrospective cohort study were classified into five stages (0-4) before TAVR based on the echocardiographic findings of cardiac damage.
Int J Cardiol Heart Vasc
February 2025
Department of Medicine, Lady Davis Carmel Medical Center, Haifa, Israel.
Background: Aortic stenosis (AS) is treated through transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR), with diabetes being prevalent among these patients. Inflammation participates in the pathogenesis of AS, and emerging evidence suggests that TAVI may exert anti-inflammatory effects. Given the established link between diabetes and inflammation, we sought to evaluate the impact of aortic valve replacement (AVR) on glycemic control.
View Article and Find Full Text PDFThromb J
January 2025
Department of Medicine, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.
Anticoagulation therapy is a critical component of post-transcatheter aortic valve implantation (TAVI) management, aimed at reducing the risk of thromboembolic events and mortality. This review examines the efficacy of continuous versus interrupted anticoagulation strategies in TAVI patients, focusing on mortality, stroke rates, and composite events. A literature review was conducted, analyzing recent studies that evaluate the impact of different anticoagulation regimens on clinical outcomes in TAVI patients.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
January 2025
Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Background: Data supporting the use of transcatheter aortic valve replacement (TAVR) for bicuspid aortic valve (BAV) is limited compared to tricuspid aortic valve (TAV) anatomy, as the BAV anatomy poses unique challenges to prosthesis expansion and symmetric deployment.
Aims: We aim to compare the acute recoil and asymmetry of the SAPIEN-3 valve between BAV and TAV anatomies and their impact on procedural outcomes.
Methods: We conducted a single-center study of patients who underwent TAVR with the SAPIEN-3 valve.
J Nurs Care Qual
January 2025
Author Affiliations: The Valve and Structural Heart Center, Morristown Medical Center, Morristown, New Jersey (Dr Worthington); and Morristown Medical Center, Morristown, New Jersey (Ms Giannantonio).
Background: Immobility in patients undergoing transcatheter aortic valve replacement (TAVR) is linked to adverse outcomes and prolonged length of stay (LOS). Advancements in TAVR procedures allow for early ambulation post-procedure.
Local Problem: In a large teaching hospital, ambulation occurred at an average of 16.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!